COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Effect of Fostair® on Biomarkers of Platelet Adhesion in Idiopathic Pulmonary Fibrosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02048644
Recruitment Status : Completed
First Posted : January 29, 2014
Last Update Posted : July 15, 2019
Chiesi Farmaceutici S.p.A.
Information provided by (Responsible Party):
Hull University Teaching Hospitals NHS Trust

Brief Summary:

The investigator has recently studied markers of platelet activation in idiopathic pulmonary fibrosis (IPF) and found that in IPF patients there is a significantly increased platelet reactivity when compared with controls which is demonstrated by a concentration dependent increase in platelet-monocyte complex formation, platelet P-selectin expression and platelet fibrinogen binding in the presence of' the platelet agonists Adenosine diphosphate and L- Threonyl- L- phenylalanyl- L- leucyl- L- leucyl- L-argininamide (TFLLR).

During platelet activation the platelets degranulate releasing numerous profibrotic cytokines including Transforming growth factor beta and Platelet derived growth factor that are recognised to be important in the pathogenesis of IPF. It is therefore plausible that the observed increased platelet reactivity in IPF contributes to the fibrotic process through local activation and degranulation with release of proinflammatory and profibrotic mediators within the pulmonary circulation.

There is evidence that corticosteroid treatment may alter platelet adhesion, in a study of spontaneously hypertensive rat (SHR) increased circulating glucocorticoid, suppressed p-selectin expression. p selectin is a transmembrane protein present in the α granules of platelets. P selectin has a crucial role in platelet aggregation and platelet-leukocyte interactions, which are both potentially important mechanisms in the initiation and/or progression of tissue injury and development of thrombosis. In a study of patients with chronic obstructive pulmonary disease (COPD) exacerbation these were treated with either β agonists alone or β agonist and 40mg prednisolone and compared with a control group. At presentation the COPD patients had higher pulmonary artery pressure (PAP) higher p selectin and fibrinogen levels but lower Antithrombin III levels (AT III). The pulmonary artery pressure and fibrinogen levels were found to be significantly decreased in the steroid treated group whilst the p-selectin levels further increased in the non steroidal therapy patients.

Rationale for the Current Study

There is a significant unmet medical need for the treatment of IPF; the only medication approved for treatment of IPF in the United Kingdom (UK) is Pirfenidone and outside the UK there is none. The main goal of the current study is to evaluate the effect of Fostair on the biomarkers of platelet activation in IPF disease which the investigator believes play a pivotal role in the pathogenesis of IPF and whether this translates in to a clinically beneficial effect of Fostair on IPF disease.

Condition or disease Intervention/treatment Phase
Idiopathic Pulmonary Fibrosis Drug: fostair Drug: placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of 28 Day Treatment With Fostair® Pressurized Metered-dose Inhaler (pMDI) 200/12 on Biomarkers of Platelet Adhesion in Patients With Idiopathic Pulmonary Fibrosis
Study Start Date : March 2014
Actual Primary Completion Date : April 2015
Actual Study Completion Date : May 2015

Arm Intervention/treatment
Placebo Comparator: placebo inhaler
matched placebo inhaler, to be taken 2 puffs, twice a day for 28 days
Drug: placebo
placebo matched inhaler 2puffs to be taken twice a day for 28 days

Experimental: fostair
fostair 100mcg/6mcg 2pufss, twice a day.
Drug: fostair
beclometasone dipropionate 200mcg and formoterol 12 mcg delivered by inhaler, twice a day for 28 days
Other Name: beclometasone dipropionate and formoterol fumarate

Primary Outcome Measures :
  1. platelet-monocyte complex formation [ Time Frame: 1 month ]
    Measurements will include platelet-monocyte complex formation measured at baseline, and post investigational treatments at Visit 5 and visit 8.

  2. platelet P-selectin expression [ Time Frame: 1 month ]
    platelet p selectin expression will be measured at baseline, and post investigational treatments at Visit 5 and visit 8.

  3. platelet fibrinogen binding [ Time Frame: 1 month ]
    Platelet fibrinogen binding will be measured at baseline, and post investigational treatments at Visit 5 and visit 8.

Secondary Outcome Measures :
  1. forced vital capacity [ Time Frame: visit1, visit 5 and visit 8 ]
    forced vital capacity will be measured at baseline and then at visit 5 and visit 8 following 1 months treatment of fostair or placebo

  2. sputum eosinophils cells [ Time Frame: 1 month ]
    inflammatory cells will be measured at baseline, and post investigational treatments at Visit 5 and visit 8.

  3. six minute walk distance [ Time Frame: 1 month ]
    six minute walk distance will be measured at baseline, and post investigational treatments at Visit 5 and visit 8.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female subjects from 40 to 85 years of age
  • Diagnosis of definite IPF according to American Thoracic Society / European respiratory symposium (ATS/ERS) Consensus Statement (2011) using either High-resolution computed tomography (HRCT) or surgical lung biopsy (SLB).
  • Carbon monoxide transfer factor (TLco) of ≥ 30 % predicted ( historical measure accepted as long as within the last year).
  • Able to maintain O2 saturation of ≥ 89% while breathing room air at rest.
  • forced vital capacity (FVC) of 50-80% predicted value
  • Negative serum pregnancy test at screening and negative urine pregnancy test at randomisation for female subjects of childbearing potential.
  • Competency to understand the information given in the Ethics Committee approved Patient Information Sheet and Consent Form; subjects must sign the form prior to the initiation of any study procedures, unless the assessment is performed as standard of care for this disease

Exclusion Criteria:

  • . Clinically significant respiratory diseases other than IPF, including asbestosis, other pneumoconiosis or hypersensitivity pneumonitis.

    • Clinically significant heart disease defined as a myocardial infarction documented by an ST elevation (STEMI) on electrocardiogram (ECG) within 6 months prior to screening, percutaneous coronary intervention or coronary artery bypass surgery within 6 months prior to screening, unstable angina pectoris, congestive heart failure (NYHA class III/IV or known left ventricular ejection fraction < 25%), ischaemic heart disease, right heart failure, significant right ventricular hypertrophy, or uncontrolled arrhythmia.
    • Current smokers
    • Use of any inhaled long acting beta-agonist or inhaled steroid within the 3 months prior to screening
    • Use of any medication to treat or possibly indicated in the treatment of IPF, such as pirfenidone, and oral corticosteroids.
    • Use of any Antiplatelet therapy which may alter assessment of study end points e.g. clopidogrel, Prasugrel, Dipyridamole etc.
    • History of cancer, precancerous state (eg, familial polyposis, breast cancer 1 (BRCA1),breast cancer 2 (BRCA2), carcinoma in-situ), other than non-melanomatous skin cancer, within 5 years prior to screening.
    • History or evidence of a clinically significant disorder, condition, or disease that, in the opinion of the investigator would pose a risk to subject safety or interfere with the study evaluations, procedures, or completion.
    • Participation in an investigational drug or device trial < 30 days prior to screening

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02048644

Layout table for location information
United Kingdom
Respiratory Medicine Clinical trials Unit
Cottingham, East Yorkshire, United Kingdom, HU16 5JQ
Sponsors and Collaborators
Hull University Teaching Hospitals NHS Trust
Chiesi Farmaceutici S.p.A.
Layout table for investigator information
Principal Investigator: Simon Hart, MD Hull University Teaching Hospitals NHS Trust
Additional Information:
Publications of Results:
Wright C, Arnell K, Fraser S, et al. S46 An RCT of 28 day treatment with Fostair® pMDI 200/12 BD on platelet biomarkers in patients with Idiopathic Pulmonary Fibrosis. Thorax 2015;70:A29-A30.

Layout table for additonal information
Responsible Party: Hull University Teaching Hospitals NHS Trust Identifier: NCT02048644    
Other Study ID Numbers: Acadmed18013
First Posted: January 29, 2014    Key Record Dates
Last Update Posted: July 15, 2019
Last Verified: July 2019
Keywords provided by Hull University Teaching Hospitals NHS Trust:
Platelets adhesion
Additional relevant MeSH terms:
Layout table for MeSH terms
Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Tissue Adhesions
Pathologic Processes
Lung Diseases
Respiratory Tract Diseases
Idiopathic Interstitial Pneumonias
Lung Diseases, Interstitial
Formoterol Fumarate
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists